SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma

By M. Son, K. Woolard, D. Nam, Jeongwu Lee, H. Fine. Cell Stem Cell, 2009

687 citations recorded by the source corpus.

SUMMARY CD133+ populations of human glioblastoma multiforme (GBM) cells are reportedly enriched for tumor stem cells (TSCs) or tumor-initiating cells (TICs). Approximately 40% of freshly isolated GBM specimens, however, do not contain CD133+ tumor cells, raising the possibility that CD133 may not be a universal enrichment marker for GBM TSCs/TICs. Here we demonstrate that stage-specific embryonic antigen 1(SSEA-1/LeX)+ GBM cells fulfill the functional criteria for TSC/TIC, since (1) SSEA-1+ cells are highly tumorigenic in vivo, unlike SSEA-1- cells; (2) SSEA-1+ cells can give rise to both SSEA-1+ and SSEA-1− cells, thereby establishing a cellular hierarchy; and (3) SSEA-1+ cells have self-renewal and multilineage differentiation potentials. A distinct subpopulation of SSEA-1+ cells was present in all but one of the primary GBMs examined (n = 24), and most CD133+ tumor cells were also SSEA-1+, suggesting that SSEA-1 may be a general TSC/TIC enrichment marker in human GBMs.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/4618261b684abfda64734a0f57e92c3e4ecd055b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Immunology

In Oncology

Citations in the corpus

Cancer stem cells: current status and evolving complexities. (2012, background): “SSEA-1 (stage-specific embryonic antigen) was identified as a CSC marker in both human glioblastoma and syngeneic mouse models of medulloblastoma (Read et al., 2009; Son et al., 2009; Ward et al., 2009).”
Integrin alpha 6 regulates glioblastoma stem cells (2010, background): “These issues underscore the need for additional markers to identify GSCs, of which several have been proposed (L1CAM, A2B5, CD15) (Bao et al., 2008; Ogden et al., 2008; Read et al., 2009; Son et al., 2009).”
Reconstructing and reprogramming the tumor propagating potential of glioblastoma stem-like cells (2014, positive): “Although putative stem-like populations in GBM can be enriched using cell surface markers such as CD133 (Singh et al., 2004), SSEA-1 (Son et al., 2009), CD44 (Anido et al., 2010), and integrin alpha 6 (Lathia et al., 2010), the consistency of the various markers and the extent to which genetic heter”
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells (2013, methodology): “GBM cells prospectively enriched by the putative GSC enrichment markers CD133 and/or CD15 (Singh et al., 2004; Son et al., 2009) were isolated from surgical specimens of GBM patients or their derivative xenograft tumors and functionally validated in assays of self-renewal and tumor propagation (Joo…”
Cancer stem cells: impact, heterogeneity, and uncertainty. (2012, result): “Work with other markers continues to support the conclusion that gliomas and medulloblastomas follow a cancer stem cell model (Read et al., 2009; Son et al., 2009; Ward et al., 2009); however, to confirm the existence and identity of cancer stem cells, it is necessary to identify markers that…”
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma (2013, methodology): “Using OLIG2 as a surrogate for CD15 (Figure S3C) as previously shown (Son et al., 2009), we found a mutually exclusive pattern of inter- and intratumoral staining with CD44 (Figures 3B, 3C, and S3D), implying that these were indeed distinct tumor populations.”